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1. DISEASE CHARACTERISTICS
1.1 Name of the disease (synonyms)
Alport syndrome.
1.2 OMIM# of the disease
301050 (X-linked form), 203780 (autosomal recessive form), and
104200 (autosomal dominant form).
1.3 Name of the analysed genes or DNA/chromosome segments
COL4A5, COL4A4, and COL4A3.
1.4 OMIM# of the gene(s)
303630 (COL4A5), 120070 (COL4A3), 120131 (COL4A4).
1.5 Mutational spectrum
COL4A5: missense mutations (B41% of the mutations; B85% of
which are glycine substitutions in the conserved Gly-Xaa-Yaa repeat
sequence in the collagenous domain of the alpha5(IV)-chain); splice
site mutations (B16%); frame shifts (small deletions, small insertions/
duplications) (B22%); nonsense mutations (B6%); large deletions,
insertions/duplications, and other larger structural rearrangements
(inversions and translocations) (B15%). More than 685 mutations
are known.
COL4A4: missense mutations (B50%;B75% of which are glycine
substitutions in the conserved Gly-Xaa-Yaa repeat sequence in the
collagenous domain of the alpha4(IV)-chain); frame shifts (small
deletions, small insertions/duplications) (B27%); splice site muta-
tions (B13%); nonsense mutations (B9%), and larger deletions
(B1%). More than 56 mutations are known.
COL4A3: missense mutations (B45% of the mutations; B85%
of which are glycine substitutions in the conserved Gly-Xaa-Yaa
repeat sequence in the collagenous domain of the alpha3(IV)-
chain); frame shifts (small deletions, small insertions/duplications)
(B21%); nonsense mutations (B15%); splice site mutations
(B15%), and larger deletions (B4%). More than 73 mutations
are known.
See:
HGMD (http://www.hgmd.org).
Alport LOVD databases (COL4A5, COL4A3, COL4A4)
(https://grenada.lumc.nl/LOVD2/COL4A/home.php?action¼switch_db).
ARUP Alport (COL4A5) database (www.arup.utah.edu/database/
ALPORT/ALPORT_welcome.php).
1.6 Analytical methods
Direct sequencing of genomic exonic DNA, including flanking intro-
nic sequences. Reverse transcriptase PCR analysis of mRNA extracted
from cultured skin fibroblasts or hair roots for deep intronic muta-
tions causing RNA splicing aberrations (X-linked form). Multiplex
ligation-dependent probe amplification (MLPA) for detection of
submicroscopic deletions and duplications. Conventional cytogenetic
analysis for detection of structural chromosome rearrangements.
Next-generation sequencing is a promising new technique for a
genetic heterogenous disorder like Alport syndrome.
1.7 Analytical validation
Confirmation in an independent biological sample from the index
case or an affected relative. Single exon deletions and duplications
should be confirmed with another technique.
1.8 Estimated frequency of the disease
(incidence at birth (‘birth prevalence’) or population prevalence)
The most widely used estimate of the prevalence of Alport syndrome
is 1:5000, based on the finding of about 300 cases in Utah and southern
Idaho in a population of 1 500 000 people.1 The incidence of Alport
syndrome was found to be 1:53000 in Finland,2 and 1:17000 in southern
Sweden.3 The inheritance is X-linked inB85% of the families, autosomal
recessive inB15%, and autosomal dominant in very few families.
1.9 If applicable, prevalence in the ethnic group of the investigated
person
Not applicable.
1.10 Diagnostic setting
Comment:
Mutation analysis is mainly used for confirmation of a clinical
diagnosis and in relation to genetic counselling. Prenatal diagnosis
and pre-implantation genetic diagnosis are available for families
with a known mutation. In families with the X-linked form of
Yes No
A. (Differential) diagnostics 2 &
B. Predictive testing 2 &
C. Risk assessment in relatives 2 &
D. Prenatal 2 &
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the disease, prenatal diagnosis is performed only after sex determina-
tion, when the foetus is male.
2. TEST CHARACTERISTICS
2.1 Analytical sensitivity
(proportion of positive tests if the genotype is present)
COL4A5: sequencing of genomic DNA and MLPA: 495%.
COL4A3 and COL4A4: sequencing of genomic DNA and MLPA:
probably 495%.
Sequence variants of unknown significance may affect the sensitivity.
2.2 Analytical specificity
(proportion of negative tests if the genotype is not present)
COL4A5: Sequencing of genomic DNA and MLPA: 495%.
COL4A3 and COL4A4: Sequencing of genomic DNA and MLPA:
495%.
2.3 Clinical sensitivity
(proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as
age or family history. In such cases, a general statement should be
given even if quantification can only be made on a case-by-case basis.
X-linked form: highly dependent on fulfillment of the clinical criteria
for Alport syndrome4 and may be supported by immunohistochemical
findings in a kidney and/or skin biopsy. Above 80% in families fulfilling
three or more diagnostic criteria. Higher in families with obvious
X-linked inheritance, and higher in males than in females.5
Autosomal recessive form: highly dependent on fulfilment of the
clinical criteria for Alport syndrome4 and may be supported by
abnormal immunohistochemical findings in a kidney biopsy, and
normal immunohistochemical findings in a skin biopsy. Above 80% in
families fulfilling three or more diagnostic criteria. Higher in families
with consanguinity, and in patients with a family history of thin
basement membrane disease/benign familial hematuria.
2.4 Clinical specificity
(proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as
age or family history. In such cases, a general statement should be
given even if quantification can only be made on a case-by-case basis.
X-linked form: almost 100% in males by the age of 20 years.
Autosomal recessive form: approaches 100% in males and females
by the age of 20 years.
2.5 Positive clinical predictive value
(life-time risk to develop the disease if the test is positive)
X-linked form: almost 100% with respect to end-stage renal disease
(ESRD) in males, and 30-40% in females.
Autosomal recessive form: almost 100% for patients with homo-
zygous or compound heterozygous COL4A3/COL4A4 mutations.
Heterozygotes can have a completely normal phenotype, or a broad
spectrum of symptoms ranging from thin basement membrane
disease/benign familial hematuria (OMIM #141200) to ESRD.
2.6 Negative clinical predictive value
(Probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected
person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested:
X-linked form: almost 100%.
Autosomal recessive form: almost 100% for patients with homo-
zygous or compound heterozygous COL4A3/COL4A4 mutations.
Heterozygotes can have a completely normal phenotype, or a broad
spectrum of symptoms ranging from thin basement membrane
disease/benign familial hematuria (OMIM #141200) to ESRD.
Index case in that family had not been tested:
X-linked form: unknown, but probably high.
Autosomal recessive form: unknown, but probably high.
3. CLINICAL UTILITY
3.1 (Differential) diagnosis: The tested person is clinically affected
(To be answered if in 1.10 ‘A’ was marked)
3.1.1 Can a diagnosis be made other than through a genetic test?
Genotype or disease A: true positives
B: false positives
C: false negative
D: true negative
Present Absent
Test
Positive A B Sensitivity:
Specificity:
A/(A+C)
D/(D+B)
Negative C D Positive predictive value:
Negative predictive value:
A/(A+B)
D/(C+D)
No & (continue with
3.1.4)
Yes 2
Clinically &
Imaging &
Endoscopy &
Biochemistry &
Electrophysiology &
Other (please
describe)
2
Family history and a clinical examination including
microscopic urine analysis, renal function study,
ophthalmoscopy, and audiometry.
Kidney biopsy: Electron microscopy for characteristic
ultrastructural changes, and immunohistochemical stain-
ing for the alpha3-, alpha4-, and alpha5-chains of type IV-
collagen. All three chains are absent in the glomerular
basement membrane (GBM), Bowman’s capsules and
tubular basement membranes in 70–80% of males with
the X-linked form. In the autosomal forms of Alport
syndrome all three chains are also absent from the GBM
in most patients, but the alpha5-chain is present in
Bowman’s capsules and tubular basement membranes.
Skin biopsy: Immunohistochemical staining for the
alpha5(IV)-chain. Absent in the epidermal basement
membrane in 70–80% of males with the X-linked form,
and normal in patients with the autosomal forms.
Recommended diagnostic procedure:
1. Family history and clinical examination.
2. Audiogram and eye examination by slit lamp
ophthalmoscopy.
3. Skin biopsy for immunohistochemical staining for the
alpha5(IV)-chain and RT-PCR analysis of mRNA from
cultured fibroblasts, or, alternatively, direct sequencing
of all 53 COL4A5 exons on genomic DNA.
4. MLPA analysis of genomic DNA for COL4A5 deletion/
duplication.6
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3.1.2 Describe the burden of alternative diagnostic methods to the
patient.
Kidney biopsy confers a risk to the patient (bleeding, infection, and
pain), and a skin biopsy will result in a tiny scar.
3.1.3 How is the cost effectiveness of alternative diagnostic methods
to be judged?
Genetic testing is useful for confirming a clinical diagnosis, informing
genetic counselling, and facilitating prenatal diagnosis and pre-
implantation genetic diagnosis. The three type-IV collagen genes,
COL4A5, COL4A3, and COL4A4, are very large genes with 48–53
exons and a coding sequence of45000bp. New technologies such as
next generation sequencing may lower costs and turn-around time.
3.1.4 Will disease management be influenced by the result of a
genetic test?
3.2 Predictive Setting: The tested person is clinically unaffected but
carries an increased risk based on family history
(To be answered if in 1.10 ‘B’ was marked)
3.2.1 Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive (please describe):
If the test is positive, clinical follow-up and genetic counselling should
be recommended. Careful management of blood pressure in a patient
with a positive predictive test prolongs the functioning life of a patient’s
native kidneys and postpones the need for renal replacement therapy.
If the test result is negative (please describe):
Clinical follow-up is not relevant if the test is negative for a known
familial mutation.
3.2.2 Which options in view of lifestyle and prevention does a person
at-risk have if no genetic test has been done (please describe)?
Avoiding potentially nephrotoxic drugs, and the same interdisciplinary
surveillance programme comprising nephrological/pediatric, ophthal-
mological, and audiological examination as for those with a positive
genetic test. The frequency depends on the clinical findings.
3.3 Genetic risk assessment in family members of a diseased person
(To be answered if in 1.10 ‘C’ was marked)
3.3.1 Does the result of a genetic test resolve the genetic situation in
that family?
Yes. The risk assessment depends on the mode of inheritance;
X-linked, autosomal recessive or dominant.
3.3.2 Can a genetic test in the index patient save genetic or other tests
in family members?
Yes. If a pathogenic mutation has been identified in the index patient,
genetic counselling and testing for the familial mutation could be
offered to relatives at risk. If a relative tests negative, then none of their
offspring are at risk and they will not need to be tested.
3.3.3 Does a positive genetic test result in the index patient enable a
predictive test in a family member?
Yes. Carrier testing and pre-symptomatic testing in relatives will be
possible.
3.4 Prenatal diagnosis
(To be answered if in 1.10 ‘D’ was marked)
3.4.1 Does a positive genetic test result in the index patient enable a
prenatal diagnosis?
Yes, prenatal and pre-implantation diagnostics can be performed in
the family, if requested.
4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate
medical consequences. Is there any evidence that a genetic test is
nevertheless useful for the patient or his/her relatives? (Please describe)
Genetic testing can be useful for the patient/family in relation to
genetic counselling. Genetic testing of relatives can also be relevant in
relation to selection of potential family donors for kidney transplantation.
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5. Direct sequencing of COL4A4 and COL4A3 on genomic
DNA in case of normal immunohistochemical staining for
the alpha5(IV)-chain of the skin biopsy and no COL4A5
mutation or if the family history suggests autosomal
inheritance (e.g. consanguineous parents).
6. Consider a kidney biopsy.
No &
Yes 2
Therapy (please
describe)
Prognosis (please
describe)
Nonsense mutations, frame shifts and larger structural
rearrangements) are associated with a younger age at
ESRD as compared with missense mutations. The first
group of mutations confer on an affected male patient a
probability of of 90% of developing ESRD before the age
of 30 years. The risk is 50% for patients with a missense
mutation.7
Deletions in the adjacent 5’-end of both COL4A5 and the
neighbouring COL4A6 gene are associated with Alport
syndrome with diffuse leiomyomatosis (OMIM #308940).
The AMME complex (Alport syndrome, mental retardation,
midface hypoplasia, and elliptocytosis; OMIM #300194)
is a contigious gene deletion syndrome which includes
deletion of COL4A5 together with neighbouring genes.
Management
(please describe)
Interdisciplinary clinical follow-up at renal/pediatric,
audiological and ophthalmological clinics. Genetic
counselling.
Angiotensin-converting enzyme inhibitors and angiotensin
II receptor blockers may reduce proteinuria and slow the
progression of the disease, although the effect need to be
confirmed in randomized, clinical trials.
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